Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
My Portfolio
Aurinia Pharm Ord
(NQ:
AUPH
)
12.35
USD
-0.25 (-1.98%)
Official Closing Price
Updated: 7:44 PM EDT, Apr 16, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,453,000
Open
12.66
Bid (Size)
12.37 (11)
Ask (Size)
12.40 (14)
Prev. Close
12.60
Today's Range
12.34 - 12.66
52wk Range
12.01 - 20.50
Shares Outstanding
127,450,815
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
April 15, 2021
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the 2021 Bloom Burton &...
From
Business Wire News Releases
Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings
April 08, 2021
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented additional efficacy data from the AURA-LV and AURORA 1 pivotal trials of LUPKYNIS™ (voclosporin) in lupus...
From
Business Wire News Releases
Performance
YTD
-8.79%
-8.79%
1 Month
-11.85%
-11.85%
3 Month
-7.21%
-7.21%
6 Month
-20.27%
-20.27%
1 Year
-20.43%
-20.43%
More News
Read More
Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report
March 15, 2021
From
Business Wire News Releases
Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences
March 02, 2021
From
Business Wire News Releases
Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
February 24, 2021
From
Business Wire News Releases
Aurinia's Lupkynis Shows Treatment Benefit In Lupus Nephritis, Additional Efficacy Data Shows
April 08, 2021
Tags
Health Care
Briefs
FDA
From
Benzinga
Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference
February 18, 2021
From
Business Wire News Releases
Aurinia Stock Has Great Potential, but It’s Not a Buy Right Now
April 07, 2021
Tags
Market News
GSK
NASDAQ:AUPH,NYSE:GSK
From
InvestorPlace
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021
February 17, 2021
From
Business Wire News Releases
The Math Shows BIB Can Go To $111
March 16, 2021
Tags
ETFs
From
ETF Channel
Earnings Preview: Aurinia Pharmaceuticals
February 23, 2021
Tags
Market News
AUPH
Benzinga
From
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.